ArticleFrontiers in neurology2025
Several proteins derived from serum exosomes are potential biomarkers for diagnosis and progression of sudden sensorineural hearing loss.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to compare the protein expression profiles of plasma-derived exosomes in patients with sudden sensorineural hearing loss (SSNHL) and normal hearing control groups to identify exosome proteins that may be associated with SSNHL or serve as biomarkers for SSNHL. Methods: Researchers collected peripheral venous blood from SSNHL patients and healthy controls for exosome isolation. The isolated exosomes were identified through nanoparticle tracking analysis, transmission electron microscopy observation, and Western blotting, followed by total protein extraction for proteomic sequencing. Differential expression proteins (DEPs) were screened using the threshold criteria of Results: Researchers isolated exosomes from plasma and identified them through particle size analysis, morphological observation, and expression of exosome marker proteins. Comparative studies with healthy individuals revealed 363 DEPs in SSNHL. Additionally, 515 DEPs were identified in mild sudden deafness (MilSSNHL) and healthy controls, 982 in moderate cases (ModSSNHL) and healthy controls, and 1,161 in profound cases (ProSSNHL) and healthy controls. These proteins are involved in signaling pathways enriched by DEPs. Validation experiments demonstrated that the expression levels of these proteins consistently matched their sequencing results, ensuring high reliability. Furthermore, these candidate proteins show significant diagnostic potential for SSNHL. Conclusion: The four extracellular proteins identified in this study, including RPS2, RPL19, ACO2 and APOE, may be closely related to the occurrence and development of SSNHL or serve as biomarkers for the diagnosis and staging of SSNHL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.